S100B expression in breast cancer as a predictive marker for cancer metastasis

Yen,Meng-Chi; Huang,Yung-Chi; Kan,Jung-Yu; Kuo,Po-Lin; Hou,Ming-Feng; Hsu,Ya-Ling

doi:10.3892/ijo.2017.4226

S100B expression in breast cancer as a predictive marker for cancer metastasis

Authors:
- Meng-Chi Yen
- Yung-Chi Huang
- Jung-Yu Kan
- Po-Lin Kuo
- Ming-Feng Hou
- Ya-Ling Hsu
View Affiliations

Affiliations: Department of Emergency Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C., Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C.
Published online on: December 12, 2017 https://doi.org/10.3892/ijo.2017.4226
Pages: 433-440

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the tumor microenvironment, soluble molecules play important role in the establishment of a pre-metastatic niche. The S100 calcium-binding protein family are inflammatory molecules that contribute to the development of a pro-inflammatory tumor microenvironment. S100B belongs to the S100 family and serum S100B (also known as S100beta) serves as a marker for metastasis in lung cancer, ovarian cancer and melanoma. However, the association between S100B and the metastasis of breast cancer is not yet well understood. In the present study, a relatively low S100B expression was observed in the tumor samples compared to normal breast tissue among online microarray datasets. When the estrogen receptor (ER)-negative breast cancer cell lines, MDA-MB-231 and Hs578T, were treated with recombinant human S100B, cell migration was significantly inhibited and epithelial cadherin expression was increased. Our results revealed that a high S100B expression predicted a good overall survival in patients with ER-negative breast cancer, and good distant metastases-free survival in all patients with breast cancer via the analysis of the KM plotter and SurvExpress databases. Although previous studies have indicated that the interaction of S100B with wild-type p53 inhibits p53 function, a high S100B expression is associated with a good prognosis in patients with p53 mutant and p53 wild-type breast cancers. On the whole, our findings demonstrate that S100B treatment suppresses the migratory capacity of ER-negative breast cancer and that S100B expression may serve a predictive marker for metastasis in breast cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Scully OJ, Bay BH, Yip G and Yu Y: Breast cancer metastasis. Cancer Genomics Proteomics. 9:311–320. 2012.PubMed/NCBI
3	Chiang AC and Massagué J: Molecular basis of metastasis. N Engl J Med. 359:2814–2823. 2008. View Article : Google Scholar : PubMed/NCBI
4	Vanharanta S and Massagué J: Origins of metastatic traits. Cancer Cell. 24:410–421. 2013. View Article : Google Scholar : PubMed/NCBI
5	Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, Psaila B, Kaplan RN, Bromberg JF, Kang Y, et al: Pre-metastatic niches: Organ-specific homes for metastases. Nat Rev Cancer. 17:302–317. 2017. View Article : Google Scholar : PubMed/NCBI
6	Lukanidin E and Sleeman JP: Building the niche: The role of the S100 proteins in metastatic growth. Semin Cancer Biol. 22:216–225. 2012. View Article : Google Scholar : PubMed/NCBI
7	Salama I, Malone PS, Mihaimeed F and Jones JL: A review of the S100 proteins in cancer. Eur J Surg Oncol. 34:357–364. 2008. View Article : Google Scholar
8	Mei Y, Yang JP and Qian CN: For robust big data analyses: A collection of 150 important pro-metastatic genes. Chin J Cancer. 36:162017. View Article : Google Scholar : PubMed/NCBI
9	Pang X, Min J, Liu L, Liu Y, Ma N and Zhang H: S100B protein as a possible participant in the brain metastasis of NSCLC. Med Oncol. 29:2626–2632. 2012. View Article : Google Scholar : PubMed/NCBI
10	Choi H, Puvenna V, Brennan C, Mahmoud S, Wang XF, Phillips M, Janigro D and Mazzone P: S100B and S100B auto-antibody as biomarkers for early detection of brain metastases in lung cancer. Transl Lung Cancer Res. 5:413–419. 2016. View Article : Google Scholar : PubMed/NCBI
11	Bonfrer JM, Korse CM, Nieweg OE and Rankin EM: The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer. 77:2210–2214. 1998. View Article : Google Scholar : PubMed/NCBI
12	Heizmann CW: S100B protein in clinical diagnostics: Assay specificity. Clin Chem. 50:249–251. 2004. View Article : Google Scholar : PubMed/NCBI
13	Schlagenhauff B, Schittek B, Ellwanger U, Stroebel W, Blum A, Schwarz M, Rassner G and Garbe C: Significance of serum protein S100 levels in screening for melanoma metastasis: Does protein S100 enable early detection of melanoma recurrence? Melanoma Res. 10:451–459. 2000. View Article : Google Scholar : PubMed/NCBI
14	Lin J, Yang Q, Wilder PT, Carrier F and Weber DJ: The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J Biol Chem. 285:27487–27498. 2010. View Article : Google Scholar : PubMed/NCBI
15	Yoshimura C, Miyafusa T and Tsumoto K: Identification of small-molecule inhibitors of the human S100B-p53 interaction and evaluation of their activity in human melanoma cells. Bioorg Med Chem. 21:1109–1115. 2013. View Article : Google Scholar : PubMed/NCBI
16	Bechmann T, Madsen JS, Brandslund I, Lund ED, Ormstrup T, Jakobsen EH, Jylling AM, Steffensen KD and Jakobsen A: Predicting brain metastases of breast cancer based on serum S100B and serum HER2. Oncol Lett. 6:1265–1270. 2013.PubMed/NCBI
17	Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thézenas S and Jacot W: Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: Predictive biomarkers for brain metastases? Int J Cancer. 139:2299–2311. 2016. View Article : Google Scholar : PubMed/NCBI
18	Charmsaz S, Hughes É, Bane FT, Tibbitts P, McIlroy M, Byrne C, Cocchiglia S, McBryan J, Hennessy BT, Dwyer RM, et al: S100β as a serum marker in endocrine resistant breast cancer. BMC Med. 15:792017. View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
20	Ma XJ, Dahiya S, Richardson E, Erlander M and Sgroi DC: Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 11:R72009. View Article : Google Scholar : PubMed/NCBI
21	Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et al: TCGA Research Network: Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 163:506–519. 2015. View Article : Google Scholar : PubMed/NCBI
22	Ringnér M, Fredlund E, Häkkinen J, Borg Å and Staaf J: GOBO: Gene expression-based outcome for breast cancer online. PLoS One. 6:e179112011. View Article : Google Scholar : PubMed/NCBI
23	Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725–731. 2010. View Article : Google Scholar
24	Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Peña JG and Treviño V: SurvExpress: An online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One. 8:e742502013. View Article : Google Scholar : PubMed/NCBI
25	Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, et al: A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res. 14:1744–1752. 2008. View Article : Google Scholar : PubMed/NCBI
26	Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G and Palacios J: Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68:989–997. 2008. View Article : Google Scholar : PubMed/NCBI
27	Chavez KJ, Garimella SV and Lipkowitz S: Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer. Breast Dis. 32:35–48. 2010. View Article : Google Scholar
28	Lamouille S, xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
29	Dominguez C, David JM and Palena C: Epithelial-mesenchymal transition and inflammation at the site of the primary tumor. Semin Cancer Biol. 47:177–184. 2017. View Article : Google Scholar : PubMed/NCBI
30	Demirkan B: The roles of epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) in breast cancer bone metastasis: Potential targets for prevention and treatment. J Clin Med. 2:264–282. 2013. View Article : Google Scholar : PubMed/NCBI
31	Giri D, Ozen M and Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 159:2159–2165. 2001. View Article : Google Scholar : PubMed/NCBI
32	Horiguchi K, Fujiwara K, Higuchi M, Yoshida S, Tsukada T, Ueharu H, Chen M, Hasegawa R, Takigami S, Ohsako S, et al: Expression of chemokine CxCL10 in dendritic-cell-like S100β-positive cells in rat anterior pituitary gland. Cell Tissue Res. 357:757–765. 2014. View Article : Google Scholar : PubMed/NCBI
33	Villarreal A, Seoane R, González Torres A, Rosciszewski G, Angelo MF, Rossi A, Barker PA and Ramos AJ: S100B protein activates a RAGE-dependent autocrine loop in astrocytes: Implications for its role in the propagation of reactive gliosis. J Neurochem. 131:190–205. 2014. View Article : Google Scholar : PubMed/NCBI
34	Nieman KM, Romero IL, Van Houten B and Lengyel E: Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 1831:1533–1541. 2013. View Article : Google Scholar : PubMed/NCBI
35	Gonçalves CA, Leite MC and Guerra MC: Adipocytes as an important source of serum S100B and possible roles of this protein in adipose tissue. Cardiovasc Psychiatry Neurol. 2010:7904312010. View Article : Google Scholar : PubMed/NCBI
36	Lim SY, Yuzhalin AE, Gordon-Weeks AN and Muschel RJ: Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells. Oncogene. 35:5735–5745. 2016. View Article : Google Scholar : PubMed/NCBI
37	Luo X, Sharff KA, Chen J, He TC and Luu HH: S100A6 expression and function in human osteosarcoma. Clin Orthop Relat Res. 466:2060–2070. 2008. View Article : Google Scholar : PubMed/NCBI
38	Bianchi R, Giambanco I and Donato R: S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COx-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol Aging. 31:665–677. 2010. View Article : Google Scholar
39	Yang T, Cheng J, Yang Y, Qi W, Zhao Y, Long H, xie R and Zhu B: S100B mediates stemness of ovarian cancer stem-like cells through inhibiting p53. Stem Cells. 35:325–336. 2017. View Article : Google Scholar